Rein Therapeutics
RNTX on Nasdaq. Market value $48m.
Should I look at this?
Look carefully before going further
Why it could be worth it
Nothing stands out yet.
What to watch out for
Read the warning sign in its own filings
This is not advice.
Who owns it
1 long-term investor we follow owns it, unchanged from 1 last quarter. 60 funds in all.
| Fund | Value | Share of that fund | Change |
|---|---|---|---|
| Voss CapitalTravis Cocke | $5m | 0.3% | Added |
Largest holders overall
- Voss Capital$5mAdded
- Cable Car Capital, LP$5mAdded
- ADAR1 Capital Management$5mNew
- Vanguard Capital Management$4mAdded
- BIOS Capital Management, LP$3mAdded
- Ikarian Capital$3mNew
- Great Point Partners$3mNew
- Citadel Advisors$3mNew
- Velan Capital Investment Management LP$2mNew
- Senvest Management$1mAdded
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
6 investors own more than 5%.
- BIOS CAPITAL MANAGEMENT, LPPassive investorat least 10.0%(filed with 23 related holders)Since 6 May 2026
- Funicular Funds, LPPassive investorat least 6.7%(filed with 2 related holders)Since 1 May 2026
- Voss CapitalPassive investorat least 6.6%−10.4 pts(filed with 4 related holders)Since 30 June 2026
- Benjamin ShapiroPassive investor6.1%Since 4 May 2026
- ADAR1 Capital Management, LLCPassive investorat least 5.3%(filed with 1 related holder)Since 30 June 2026
- Lynwood Capital Management Inc.Passive investorat least 5.0%−1.1 pts(filed with 2 related holders)Since 30 June 2026
- LYTTON LAURENCE WPassive investorSold down below 5%Since 30 June 2026
| Holder | Stake | Since | |
|---|---|---|---|
BIOS CAPITAL MANAGEMENT, LP Passive investor | at least 10.0% (filed with 23 related holders) | 6 May 2026 | |
Funicular Funds, LP Passive investor | at least 6.7% (filed with 2 related holders) | 1 May 2026 | |
Voss Capital Passive investor | at least 6.6%−10.4 pts (filed with 4 related holders) | 30 June 2026 | |
Benjamin Shapiro Passive investor | 6.1% | 4 May 2026 | |
ADAR1 Capital Management, LLC Passive investor | at least 5.3% (filed with 1 related holder) | 30 June 2026 | |
Lynwood Capital Management Inc. Passive investor | at least 5.0%−1.1 pts (filed with 2 related holders) | 30 June 2026 | |
LYTTON LAURENCE W Passive investor | Sold down below 5% | 30 June 2026 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
In the last 12 months, 2 insiders bought $74,701 of shares on the open market.
- VON RICKENBACH JOSEF HDirectorBought
- Date
- 27 May 2026
- Shares
- 4,500
- Price
- $1.07
- Value
- $4,815
- VON RICKENBACH JOSEF HDirectorBought
- Date
- 26 May 2026
- Shares
- 23,190
- Price
- $1.06
- Value
- $24,581
- VON RICKENBACH JOSEF HDirectorBought
- Date
- 22 May 2026
- Shares
- 15,950
- Price
- $1.05
- Value
- $16,748
- VON RICKENBACH JOSEF HDirectorBought
- Date
- 21 May 2026
- Shares
- 3,420
- Price
- $1.04
- Value
- $3,557
- WINDSOR JAMES BRIANSee Remarks, DirectorBought
- Date
- 30 April 2026
- Shares
- 25,000
- Price
- $1.00
- Value
- $25,000
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 27 May 2026 | VON RICKENBACH JOSEF H Director | Bought | 4,500 | $1.07 | $4,815 |
| 26 May 2026 | VON RICKENBACH JOSEF H Director | Bought | 23,190 | $1.06 | $24,581 |
| 22 May 2026 | VON RICKENBACH JOSEF H Director | Bought | 15,950 | $1.05 | $16,748 |
| 21 May 2026 | VON RICKENBACH JOSEF H Director | Bought | 3,420 | $1.04 | $3,557 |
| 30 April 2026 | WINDSOR JAMES BRIAN See Remarks, Director | Bought | 25,000 | $1.00 | $25,000 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
1 serious warning sign in Rein Therapeutics’ filings.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 26 Mar 2026, plus the 10-Q filed 16 Nov 2026 and 5 later 8-Ks.
Weak checks on its own accounts
SeriousThe company said its checks on its own accounts did not work at the end of its latest quarter. Mistakes could slip into the numbers.
“Based on that evaluation, our Chief Executive Officer and our interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026, because of the identified material weaknesses in our internal control over financial reporting described below.”
Show the full paragraph
Our management, with the participation of our Chief Executive Officer and our interim Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and our interim Chief Financial Officer concluded that our disclosure controls and procedures were not effective at the reasonable assurance level as of September 30, 2026, because of the identified material weaknesses in our internal control over financial reporting described below.
From the 10-Q filed 16 November 2026, Part I, Item 4. Controls and Procedures. Read it in the filing
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.